XOMA welcomes Natasha Hernday to its Board of Directors

– USA, CA –  XOMA Corporation (NASDAQ: XOMA) announced today the appointment of Natasha A. Hernday, SVP, Corporate Development at Seattle Genetics, Inc., to its Board of Directors.

Ms. Hernday has 20 years of experience in corporate development and corporate strategy work and an extensive record of asset licensing, partnerships, and acquisition transactions.

“We graciously welcome Natasha to the XOMA Board of Directors. Natasha has had an exceptional career in corporate development, both at Seattle Genetics and at Amgen. Her expertise in sourcing, evaluating and negotiating licensing deals, acquisitions, and partnerships are complementary to our royalty aggregator business model and are expected to benefit XOMA and our stakeholders as we continue to build our royalty portfolio,” said CEO, Jim Neal.

About

Ms. Hernday joined Seattle Genetics in 2011 and is responsible for the Company’s in-licensing, collaboration and acquisition transactions, in addition to serving as a member of the Executive Committee. Notably, her team led the 2018 acquisition of Cascadian Therapeutics, which included TUKYSA, which received marketing approval in the U.S. and Switzerland in 2020. Prior to joining Seattle Genetics, she spent 16 years at Amgen, initially in research, then transitioning into project management and ultimately corporate development. Ms. Hernday has served on the Board at PDL BioPharma, Inc., since June 2019.

“XOMA’s royalty aggregator business model focuses heavily on business development activities within the biotech industry to benefit patients and shareholders. These align with my personal passions and professional expertise. I look forward to joining the XOMA Board to help the Company further its mission of advancing breakthroughs in human health through its royalty aggregation strategy,” commented Ms. Hernday.

Ms. Hernday received her Masters in Business and Administration from Pepperdine University and her Bachelor’s degree in Microbiology with an emphasis on Medical Microbiology from the University of California Santa Barbara.

About XOMA Corporation

XOMA has built a significant portfolio of products that are licensed to and being developed by other biotechnology and pharmaceutical companies. The Company’s portfolio of partner-funded programs spans multiple stages of the drug development process and across various therapeutic areas. Many of these licenses are the result of XOMA’s pioneering efforts in the discovery and development of antibody therapeutics. The Company’s royalty-aggregator business model includes acquiring additional licenses to programs with third-party funding.

For more information: https://www.xoma.com

- DisclaimerNews, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.

Talent4Boards Team

here the original post =>